Compare ACFN & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | RNTX |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | 27 | 10 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.8M | 47.7M |
| IPO Year | N/A | N/A |
| Metric | ACFN | RNTX |
|---|---|---|
| Price | $18.39 | $1.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 12.5K | ★ 118.7K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $1.02 |
| 52 Week High | $33.00 | $2.22 |
| Indicator | ACFN | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 68.65 |
| Support Level | $18.16 | $1.08 |
| Resistance Level | $19.87 | $2.18 |
| Average True Range (ATR) | 0.99 | 0.19 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 63.27 | 81.65 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.